Small Cell Lung Cancer

P=N/A, N=58, Active, not recruiting, Wake Forest University Health Sciences | Recruiting --> Active, not recruiting | N=244 --> 58

They suppress SCLC antigen presentation via ferroptosis-dependent/independent mechanisms, limiting T cell function. TRIM36 and CAMK2N2 are promising SCLC biomarkers and therapeutic targets, providing clues to unravel ferroptosis-antigen presentation associations in tumor cells and optimize immunotherapeutic strategies.

Furthermore, clonal evolution analysis revealed that the two tumor components shared a set of 160 identical somatic mutations (accounting for approximately 16% of the total mutations in each component). This study delineates a dynamic evolutionary process within the pulmonary neuroendocrine tumor spectrum, confirming that a subset of atypical carcinoids can progress to small cell lung carcinoma through a transformation pathway.

The SPR‑POF platform demonstrated portability, cost-effectiveness (estimated 5 USD/unit), and operational simplicity, highlighting its potential for point-of-care testing (POCT) applications. Although limited by small patient numbers, these findings support MAVS as a promising predictive biomarker in SCLC, warranting validation in larger prospective studies.

More importantly, RB1 functional status may also modulate sensitivity to additional therapeutic modalities, highlighting its broader relevance to the evolving SCLC treatment landscape. Integrating molecularly informed strategies accounting for RB1 proficiency and its transcriptional landscape will be pivotal to overcoming the long-standing therapeutic impasse in SCLC, offering a roadmap for the development of effective, precision-guided therapies.

P1, N=339, Recruiting, Zai Lab (Shanghai) Co., Ltd. | N=112 --> 339

P1, N=40, Not yet recruiting, National Cancer Institute (NCI)

A personalised surveillance strategy may provide a novel avenue to monitor SCLC, supporting further investigation and potential broader clinical application.

Despite timely whole-brain radiotherapy and chemotherapy, his condition deteriorated rapidly, and he succumbed within weeks. This case highlights the rare presentation of small-cell lung carcinoma with cutaneous metastases, which is associated with poor prognosis.

These updated European guidelines provide a comprehensive framework for standardized, high-quality care in stage I-III SCLC and establish a reference standard to harmonize radiotherapy approaches and inform the design of upcoming clinical trials.

This study identified three distinct SCLC phenotypes with unique therapeutic vulnerabilities. An ANXA1High subset within the immune-rich infiltrated phenotype showed ICI resistance, offering new strategies to enhance ICI efficacy.

Upregulated genetically determined plasma HGF levels were associated with an increasing risk of lung cancer, especially for LUAD. Mediated regulation of EGF on these associations indicated a potential pathogenesis pathway in lung cancer, which provides important implications for the prevention and management of lung cancer.